Clinical trials: FSGS
Focal Segmental Glomerulosclerosis
Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5
This study is a proof-of-concept clinical study designed to test the hypothesis that oral administration of galactose can lower the level of a circulating factor that increases glomerular permeability to albumin in patients with…
- Trial name
- NCT00816504
- Testing
- Galactose
- Where
- United States
- Sponsor
- Northwell Health
Primary Focal Segmental Glomerulosclerosis
A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
The purpose of this study is to determine whether Rituximab therapy is safe and effective in treating patients with the kidney condition, focal segmental glomerulosclerosis (FSGS), that is no longer responsive to traditional…
- Trial name
- NCT01573533
- Testing
- Rituximab
- Where
- 4 sites in United States, Canada
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Kidney Diseases
Global Kidney Patient Trials Network
This is a prospective international multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease
- Trial name
- GKPTN (NCT04389827)
- Where
- Australia
- Volunteers
- 5,999 people
- Sponsor
- The George Institute
Focal Segmental Glomerulosclerosis
Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)
The purpose of this study is to evaluate the safety and tolerability of FG-3019 administered over 8 weeks to adolescent and adult subjects with steroid-resistant focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT00782561
- Testing
- FG-3019
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Kyntra Bio
Nephrotic Syndrome in Children, Minimal Change Disease
A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)
Children with steroid resistant nephrotic syndrome (SRNS) are exposed to prolonged courses of immunosuppressant medications. Given the adverse side effect profiles and variable efficacy of these medications, there is an urgent…
- Conditions
- Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
- Trial name
- kidNEY-VNS (NCT05583942)
- Testing
- trascutaneous auricular vagus nerve stimulation
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Northwell Health
Kidney Diseases
China Kidney Patient Trials Network
This is a prospective multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease in China.
- Trial name
- CKPTN (NCT05036850)
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- George (Beijing) Clinical Research Co. Ltd.
SIOD, Cystinosis
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
This is a single center, non-randomized, non-controlled open-label phase 1b/2a trial of performing sequential αβdepleted-HSCT and KT in patients requiring KT to prevent kidney rejection post-KT, in the absence of any post-KT…
- Conditions
- SIOD, Cystinosis, FSGS, SLE Nephritis
- Trial name
- NCT05508009
- Testing
- Cyclophosphamide 1200 mg/Kg, Fludarabine, Cyclophosphamide 100 mg/Kg
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Alice Bertaina
Focal Segmental Glomerulosclerosis
LDL-Apheresis for FSGS CardioRenal Outcomes
Focal segmental glomerulosclerosis (FSGS) is the most common cause of end-stage renal disease (ESRD) in adolescents. The refractory nature of FSGS and a more than 30% recurrence rate after kidney transplantation renders treatment…
- Trial name
- NCT04088799
- Testing
- No intervention
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
FSGS, Proteinuria
Rituximab to Prevent Recurrence of Proteinuria
The investigators propose to study novel targets of rituximab in podocytes, with a particular focus on recurrent focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT01164098
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- George W. Burke
Minimal Change Disease (MCD), Membranous Nephropathy
Nephrotic Syndrome Study Network
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage…
- Conditions
- Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
- Trial name
- NEPTUNE (NCT01209000)
- Testing
- Kidney Biopsy
- Where
- 44 sites in United States, Canada
- Volunteers
- 1,200 people
- Sponsor
- University of Michigan
Fluid Overload, Glomerulosclerosis, Focal Segmental
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
Researchers from the University of Michigan and Northwestern University are studying people's experiences with swelling caused by Nephrotic Syndrome.
- Conditions
- Fluid Overload, Glomerulosclerosis, Focal Segmental, Edema, Membranous Nephropathy
- Trial name
- Prepare-NS (NCT05505500)
- Testing
- Interview
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Michigan
Childhood Idiopathic Nephrotic Syndrome
Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood
Background Idiopathic nephrotic syndrome is a rare disease beginning during childhood and treated with immunosuppressants (i.e. steroids, mycophenolate mofetil, cyclophosphamide, cyclosporine).
- Trial name
- NEPHRUTIX (NCT01268033)
- Testing
- Rituximab
- Where
- 24 sites in Belgium, France
- Volunteers
- 26 people
- Sponsor
- University Hospital, Limoges
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in quality of life, edema, early graft loss and…
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD
- Trial name
- RESOLVE (NCT05650619)
- Testing
- Biospecimen collection, Data collection
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Michigan
Focal Segmental Glomerulosclerosis, HIV-Associated Focal Segmental Glomerulosclerosis
Genetic Markers for Focal Segmental Glomerulosclerosis
Glomerulonephritis is a disease which affect the kidneys. Occasionally these diseases can progress to a loss of kidney function in some patients.
- Trial name
- NCT00001393
- Where
- United States
- Volunteers
- 616 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Alport Syndrome, Focal Segmental Glomerulosclerosis
Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
This is a Phase 2, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary…
- Trial name
- NCT05267262
- Testing
- R3R01
- Where
- 22 sites in United States, Belgium and 4 more
- Volunteers
- 43 people
- Sponsor
- River 3 Renal Corp.
Focal Glomerulosclerosis
Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)
The current management of primary FSGS is predicated on the assumption that the disease is caused by an immune-mediated disturbance in glomerular barrier function.
- Trial name
- NCT00193648
- Testing
- Rosiglitazone (Avandia), Adalimumab (Humira)
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Northwell Health
Focal Segmental Glomerulosclerosis, Steroid Resistant Nephrotic Syndrome
Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome
Focal Segmental Glomerulosclerosis (FSGS) is a devastating kidney disease which is difficult to treat and carries a poor prognosis, with 50% of affected children progressing to end stage renal disease (ESRD).
- Trial name
- NCT01113385
- Testing
- D-Galactose
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Children's National Research Institute
Nephrotic Syndrome in Children, Minimal Change Disease
taVNS for FRNS in Children
Children with frequently relapsing nephrotic syndrome (FRNS) are exposed to prolonged courses of steroids and other immunosuppressant medications.
- Conditions
- Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
- Trial name
- kidNEY-VNS (NCT05588063)
- Testing
- Transcutaneous auricular vagus nerve stimulation
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Northwell Health
Focal Segmental Glomerulosclerosis
Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial
This project will test whether adalimumab,and/or galactose can safely reduce proteinuria (abnormal amounts of protein in the urine) and protect kidney function better than standard treatment for patients with focal segmental…
- Trial name
- FONTII (NCT00814255)
- Testing
- Adalimumab, Lisinopril, losartan, and atorvastatin, galactose
- Where
- 18 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- NYU Langone Health
Glomerulonephritis, Nephrotic Syndrome
Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis
This study will test the safety and effectiveness of a monthly dosing regimen of dexamethasone-a strong steroid medication-to treat patients with focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT00004990
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)